CancerDrs

Colorectal Cancer clinical trials in Kentucky

18 actively recruiting colorectal cancer trials at 8 sites across Kentucky.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Network

Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors

This phase III trial evaluates whether a web-based intervention called Current Together after Cancer (CTAC) works to increase the number of patients with surgically removed (resected) colorectal cancer who receive surveillance care that al…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT07018869
Sites in Kentucky:
  • Flaget Memorial Hospital — Bardstown, Kentucky
  • Commonwealth Cancer Center-Corbin — Corbin, Kentucky
  • Saint Joseph Hospital — Lexington, Kentucky
  • Saint Joseph Radiation Oncology Resource Center — Lexington, Kentucky
  • Saint Joseph Hospital East — Lexington, Kentucky
Phase 3 Recruiting Network

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

This phase III trial compares hepatic arterial infusion (HAI) (pump chemotherapy) in addition to standard of care chemotherapy versus standard of care chemotherapy alone in treating patients with colorectal cancer that has spread to the li…

Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT05863195
Sites in Kentucky:
  • University of Kentucky/Markey Cancer Center — Lexington, Kentucky
Phase 3 Recruiting Industry

Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

The primary purpose of this study is to evaluate the efficacy of perioperative dostarlimab compared with standard of care (SOC) in participants with untreated T4N0 or Stage III (resectable), defective mismatch repair/ microsatellite instab…

Sponsor: GlaxoSmithKline
NCT ID: NCT05855200
Sites in Kentucky:
  • GSK Investigational Site — Lexington, Kentucky
  • GSK Investigational Site — Louisville, Kentucky
Phase 3 Recruiting Industry

A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

Researchers are looking for other ways to treat locally advanced or metastatic colorectal cancer (mCRC) that is unresectable and has a gene mutation called KRAS G12C. Standard (or usual) treatments for this type of colorectal cancer may in…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06997497
Sites in Kentucky:
  • University of Kentucky ( Site 0055) — Lexington, Kentucky
  • Norton Cancer Institute, Audubon Hospital Campus ( Site 0054) — Louisville, Kentucky
Phase 2 Recruiting Academic/Other

Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial

This phase III trial compares the addition of total ablative therapy to the usual systemic therapy versus the usual systemic therapy alone in treating patients with advanced colorectal cancer that has spread to up to 4 body sites (limited …

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05673148
Sites in Kentucky:
  • University of Kentucky/Markey Cancer Center — Lexington, Kentucky
  • Baptist Health Louisville — Louisville, Kentucky
Phase 1, Phase 2 Recruiting Industry

Lead-212 PSV359 Therapy for Patients With Solid Tumors

Phase I/IIa image-guided, alpha-particle therapy study of \[203Pb\]Pb-PSV359 and \[212Pb\]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.

Sponsor: Perspective Therapeutics
NCT ID: NCT06710756
Sites in Kentucky:
  • University of Kentucky — Lexington, Kentucky
Phase 1, Phase 2 Recruiting Industry

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

This is a first-in-human, Phase 1/2, open-label, dose escalation and dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Spevatamig (PT886). Pa…

Sponsor: Phanes Therapeutics
NCT ID: NCT05482893
Sites in Kentucky:
  • Norton Cancer Institute — Louisville, Kentucky
Phase 1, Phase 2 Recruiting Industry

A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P03 monotherapy in adult patients with s…

Sponsor: Alentis Therapeutics AG
NCT ID: NCT07169734
Sites in Kentucky:
  • Norton Cancer Institute - Norton Healthcare Pavilion — Louisville, Kentucky
Phase 2 Recruiting Academic/Other

Trial of the Efficacy and Safety of Short and Long Course Radiation Therapy With/Without BMX-001

In this Phase 2 study, we will conduct an efficacy and safety study of the combination of investigational drug BMX-001, with short-course radiotherapy (SCRT) or long-course chemoradiotherapy (LCCRT) as part of total neoadjuvant therapy in …

Sponsor: University of Nebraska
NCT ID: NCT05254327
Sites in Kentucky:
  • Markey Cancer Center — Lexington, Kentucky
Phase 1 Recruiting Industry

A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

This is a first-in-human, Phase I, open-label, multicenter, dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of VVD-133214 monotherapy, a…

Sponsor: Vividion Therapeutics, Inc.
NCT ID: NCT06004245
Sites in Kentucky:
  • Norton Cancer Institute - MDC — Louisville, Kentucky
Phase 1 Recruiting Industry

A Study of ASP1002 in Adults for Treatment of Solid Tumors

ASP1002 is being studied in people with tumors that have spread to nearby tissue (locally advanced) that cannot be removed by surgery (unresectable) or tumors that have spread to other parts of the body (metastatic). Claudin 4 protein, or …

Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT05719558
Sites in Kentucky:
  • Norton Cancer Institute — Louisville, Kentucky
Recruiting Academic/Other

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …

Sponsor: Wake Forest University Health Sciences
NCT ID: NCT06418204
Sites in Kentucky:
  • Flaget Memorial Hospital — Bardstown, Kentucky
  • Saint Joseph Hospital East — Lexington, Kentucky
  • Saint Joseph London — London, Kentucky
  • Saint Joseph Mount Sterling — Mount Sterling, Kentucky
  • Mercy Health - Paducah Cancer Center — Paducah, Kentucky
NA Recruiting Academic/Other

Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays

This study seeks to learn whether using the PAGODA algorithm to guide chemotherapy dosing will lower the chance of unplanned delays during chemotherapy for cancer in the gastrointestinal system compared to usual care.

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07283939
Sites in Kentucky:
  • CommonSpirit Saint Joseph Hospital - Bardstown — Bardstown, Kentucky
  • Commonwealth Cancer Center-Corbin — Corbin, Kentucky
  • CommonSpirit Saint Joseph Hospital - Lexington — Lexington, Kentucky
  • Saint Joseph Radiation Oncology Resource Center — Lexington, Kentucky
  • CommonSpirit Saint Joseph Medical Center - East Lexington — Lexington, Kentucky
Recruiting Industry

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, …

Sponsor: Adela, Inc
NCT ID: NCT05366881
Sites in Kentucky:
  • Baptist Corbin — Corbin, Kentucky
  • Baptist Hardin — Elizabethtown, Kentucky
  • Baptist Lexington — Lexington, Kentucky
  • Baptist Paducah — Paducah, Kentucky
Recruiting Industry

EXoPERT EMERALD Clinical Study

The purpose of this study is to establish a multi-center clinical repository of blood samples to support the development and evaluation of an artificial intelligence-based in vitro diagnostic software. The software analyzes surface-enhance…

Sponsor: EXoPERT
NCT ID: NCT07186296
Sites in Kentucky:
  • Lexington VA Healthcare System — Lexington, Kentucky
  • KCTL — Louisville, Kentucky
NA Recruiting Academic/Other

GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care

This is a prospective, randomized study designed to compare genotype-guided dosing to usual care in patients with pancreas cancer and colorectal cancer who are UGT1A1 intermediate metabolizers (\*1/\*28) (heterozygotes) and usual UGT metab…

Sponsor: Reema A. Patel
NCT ID: NCT05391126
Sites in Kentucky:
  • University of Kentucky — Lexington, Kentucky

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-01